Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giving Upfront Anti-p40 to Reduce Toxicity from Dual Immune Checkpoint Inhibition in Mesothelioma
2026-526036-38-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ustekinumab in pleural mesothelioma, sponsored by Erasmus MC. Primary endpoint: Incidence of severe immune-related adverse events within 24 weeks. Planned start Jul 2026; status: authorised.
02
Drugs
ustekinumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2026-526036-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526036-38-00.